Structure-permeation relationships for the non-invasive transdermal delivery of cationic peptides by iontophoresis
- PMID: 16837178
- DOI: 10.1016/j.ejps.2006.05.012
Structure-permeation relationships for the non-invasive transdermal delivery of cationic peptides by iontophoresis
Abstract
Transdermal iontophoresis enables the controlled, non-invasive administration of peptide therapeutics. The aims of this study were (i) to evaluate the effect of amino acid sequence and the spatial distribution of peptide physicochemical properties on electrotransport, and (ii) to develop a quantitative model to predict peptide transport rates. Experimental results showed that the distribution of molecular properties over the peptide surface significantly affected iontophoretic delivery: different arrangements of the same residues resulted in different transport behavior. Computational studies generated three-dimensional quantitative structure-permeation relationships (3D-QSPR) based on 3D descriptors. The model predicted that iontophoresis was favored by peptide hydrophilicity but hindered by voluminous, localized hydrophobicity. Molecular characteristics that favor electrotransport are the converse of those required for passive diffusion across biological membranes. The data represent the first analysis of peptide electrotransport in terms of the spatial distribution of molecular properties and provide insight into the ab initio prediction of transdermal iontophoretic peptide delivery.
Similar articles
-
Effect of amino acid sequence on transdermal iontophoretic peptide delivery.Eur J Pharm Sci. 2005 Dec;26(5):429-37. doi: 10.1016/j.ejps.2005.07.012. Epub 2005 Sep 6. Eur J Pharm Sci. 2005. PMID: 16143501
-
Combined effects of iontophoretic and chemical enhancement on drug delivery. II. Transport across human and murine skin.Int J Pharm. 2007 Aug 16;341(1-2):114-24. doi: 10.1016/j.ijpharm.2007.04.004. Epub 2007 Apr 6. Int J Pharm. 2007. PMID: 17502130
-
Non-invasive iontophoretic delivery of enzymatically active ribonuclease A (13.6 kDa) across intact porcine and human skins.J Control Release. 2010 Aug 3;145(3):203-9. doi: 10.1016/j.jconrel.2010.04.020. Epub 2010 Apr 25. J Control Release. 2010. PMID: 20423719
-
Non-invasive iontophoretic delivery of peptides and proteins across the skin.Expert Opin Drug Deliv. 2011 May;8(5):645-63. doi: 10.1517/17425247.2011.566265. Epub 2011 Mar 24. Expert Opin Drug Deliv. 2011. PMID: 21428867 Review.
-
Mathematical models to describe iontophoretic transport in vitro and in vivo and the effect of current application on the skin barrier.Adv Drug Deliv Rev. 2013 Feb;65(2):315-29. doi: 10.1016/j.addr.2012.04.012. Epub 2012 May 22. Adv Drug Deliv Rev. 2013. PMID: 22626977 Review.
Cited by
-
Rational Design of Topical Semi-Solid Dosage Forms-How Far Are We?Pharmaceutics. 2023 Jun 26;15(7):1822. doi: 10.3390/pharmaceutics15071822. Pharmaceutics. 2023. PMID: 37514009 Free PMC article. Review.
-
Structure-skin permeability relationship of dendrimers.Pharm Res. 2011 Sep;28(9):2246-60. doi: 10.1007/s11095-011-0455-0. Epub 2011 Jun 2. Pharm Res. 2011. PMID: 21633876
-
Transdermal delivery of cytochrome C--A 12.4 kDa protein--across intact skin by constant-current iontophoresis.Pharm Res. 2007 Jul;24(7):1360-8. doi: 10.1007/s11095-007-9294-4. Epub 2007 Apr 25. Pharm Res. 2007. PMID: 17457661
-
Non-Invasive Delivery of Negatively Charged Nanobodies by Anodal Iontophoresis: When Electroosmosis Dominates Electromigration.Pharmaceutics. 2024 Apr 13;16(4):539. doi: 10.3390/pharmaceutics16040539. Pharmaceutics. 2024. PMID: 38675200 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources